Clinical epidemiology: Diagnostic and prognostic tests

Current Opinion in Rheumatology

Volumn 15, Issue 2, 2003, Pages 104-109

  Ward, Michael M ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; EPITOPE; FILAGGRIN; NEUTROPHIL CYTOPLASMIC ANTIBODY;

DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DISEASE ASSOCIATION; EROSION; HUMAN; LEUKOCYTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; SEROLOGY; SYNOVITIS;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; DIAGNOSTIC IMAGING; FEMALE; HISTOCOMPATIBILITY TESTING; HLA-DR1 ANTIGEN; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RHEUMATOID FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 0037373358     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200303000-00003     Document Type: Review

References (53)

1. van Boekel MAM, Vossenaar ER, van den Hoogen FHJ, et al.: Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002, 4:87-93. • A concise review of antifilaggrin autoantibodies and other autoantibody systems in RA.
2. Ferraro-Peyret C, Tebib J, Desbos A, et al.: Improvement in diagnosis of rheumatoid arthritis using dual indirect immunofluorescence and immunblotting assays for antifilaggrin autoantibodies: a retrospective 3 year study. J Rheumatol 2002, 29:276-281.
3. Saraux A, Berthelot JM, Chales G, et al.: Value of laboratory tests in early prediction of rheumatoid arthritis. Arthritis Rheum (Arthritis Care Res) 2002, 47:155-165. •• Prospective assessment of many diagnostic laboratory tests, including antiperinuclear factor and antikeratin antibodies, in a large cohort of patients with early arthritis presenting to rheumatologists.
4. Vincent C, Nogueira L, Sebbag M, et al.: Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis. Arthritis Rheum 2002, 46:2051-2058.
5. Nogueira L, Sebbag M, Vincent C, et al.: Performance of two ELISAs for antifilaggrin autoantibodies, using either affinity purified or deiminated recombinant human filaggrin, in the diagnosis of rheumatoid arthritis. Ann Rheum Dis 2001, 60:882-887.
6. Bas S, Perneger TV, Seitz M, et al.: Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology 2002, 41:809-814.
7. Bizzaro N, Mazzanti G, Tonutti E, et al.: Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001,47:1089-1093.
8. McQueen FM: Magnetic resonance imaging in early inflammatory arthritis: what is its role? Rheumatol 2000, 39:700-706.
9. Ostendorf B, Peters R, Dann P, et al.: Magnetic resonance imaging and miniarthroscopy of metacarpophalangeal joints: sensitive detection of morphologic changes in rheumatoid arthritis. Arthriits Rheum 2001, 44:2492-2502. • Rarely performed validation study comparing MRI changes with macroscopically observed changes in synovium, bone, and cartilage using arthroscopy.
10. Savnik A, Malmskov H, Thomsen HS, et al.: Magnetic resonance imaging of the wrist and finger joints in patients with inflammatory joint diseases. J Rheumatol 2001, 28:2193-2200.
11. Savnik A, Malmskov H, Thomsen HS, et al.: MRI of the wrist and finger joints in inflammatory joint diseases at 1 -year interval: MRI features to predict bone erosions. Eur Radiol 2002, 12:1203-1210.
12. Backhaus M, Burmester GR, Sandrock D, et al.: Prospective two year follow up study comparing novel and conventional imaging procedures in patients with arthritic finger joints. Ann Rheum Dis 2002, 61:895-904.
13. Szkudlarek M, Court-Payen M, Strandberg C, et al.: Power Doppler ultrasonography for assessment of synovitis in the metacarpophalangeal joints of patients with rheumatoid arthritis: a comparison with dynamic magnetic resonance imaging. Arthritis Rheum 2001, 44:2018-2023.
14. Scheel AK, Krause A, Rheimbeben IM, et al.: Assessment of proximal finger joint inflammation in patients with rheumatoid arthritis, using a novel laser-based imaging technique. Arthritis Rheum 2002, 46:1177-1184.
15. Visser H, le Cessie S, Vos K, et al.: How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002, 46:357-365.
16. Bas S. Perneger TV, Kunzle E, et al.: Comparative study of different enzyme immunoassays for measurement of IgM and IgA rheumatoid factors. Ann Rheum Dis 2002, 61:505-510.
17. Saulot V, Vittecoq O, Charlionet R, et al.: Presence of autoantibodies to the glycolytic enzyme alpha-enolase in sera from patients with rheumatoid arthritis. Arthritis Rheum 2002, 46:1196-1201.
18. Vittecoq O, Salle V, Jouen-Beades F, et al.: Autoantibodies to the 27 C-terminal amino acids of calpastatin are detected in a restricted set of connectire tissue diseases and may be useful for diagnosis of rheumatoid arthritis in community cases of very early arthritis. Rheumatology 2001, 40:1126-1134.
19. Jansen LMA, van der Horst-Bruinsma IE, van Schaaldenburg D, et al.: Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 2001, 60:924-927.
20. Bukhari M, Lunt M, Harrison BJ, et al.: Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum 2002, 46:906-912.
21. Drossaers-Bakker KW, Zwinderman AH, Vlieland TF, et al.: Long.term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. Arthritis Rheum (Arthritis Care Res) 2002, 47:393-390.
22. Garnero P, Gineyts E, Christgau S, et al.: Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collage C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum 2002, 46:21-30.
23. Gorman JD, Criswell LA: The shared epitope and severity of rheumatoid arthritis. Rheum Dis Clin North Am 2002, 28:59-78. • A comprehensive review of prior studies of this association, with emphasis on reasons for discrepancies among studies.
24. Constantin A, Lauwers-Cances V, Navaux F, et al.: Collagenase-1 (MMP-1) and HLA-DRB1 gene polymorphisms in rheumatoid arthritis: a prospective longitudinal study. J Rheumatol 2002, 29:15-20.
25. Constantin A, Lauwers-Cances V, Navaux F, et al.: St'omelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms: association with severity and progression of rheumatoid arthritis in a prospective study. Arthritis Rheum 2002, 46:1754-1762.
26. Massardo L, Gareca N, Cartes MA, et al.: The presence of the HLA-DRB1 shared epitope correlates with erosive disease in Chi ean patients with rheumatoid arthritis. Rheumatology 2002, 41:153-156.
27. Citera G, Padulo LA, Fernandez G, et al.: Influence of HLA-DR alleles on rheumatoid arthritis: susceptibility and severity in Argentine patients. J Rheumatol 2001, 28:1486-1491.
28. Mattey DL, Hassell AB, Dawes PT, et al.: Independent association of rheumatoid factor and the HLA-DRB1 shared epitope with radiographic outcome in rheumatoid arthritis. Arthritis Rheum 2001, 44:1529-1533.
29. Lard LR, Boers M, Verhoeven A, et al.: Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum 2002, 46:899-905. •• Analysis of two treatment trials demonstrating that early treatment with disease-modifying medications or combination treatment can attenate the association between the shared epitope and the progression of bone damage assessed by radiographs.
30. Gonzalez-Gay MA, Hajeer AH, Garcia-Porrua C, et al.: Patients chosen for treatment with cyclosporine because of severe rheumatoid arthritis are more likely to carry HLA-DRB1 shared epitope alleles, and have earlier disease onset. J Rheumatol 2002, 29:271-275.
31. McKibbin M, Clark B, Isaacs JD, et al.: Does the shared epitope genotype influence either the susceptibility to or the phenotype of corneal melting? Eye 2001, 15:492-496.
32. Sieper J, Rudwaleit M, Braun J, et al.: Diagnosing reactive arthritis. Role of clinical setting in the value of serological and microbiologic assays. Arthritis Rheum 2002, 46:319-327. • Testing algorithms for the evaluation of patients with suspected reactive arthritis are presented.
33. Schnarr S, Putschky N, Jendro MC, et al.: Chalmydia and Borrelia DNA in synovial fluid of patients with early undifferentiated olgoarthritis: results of a prospective study. Arthritis Rheum 2001, 44:2679-2685.
34. Balint PV, Kane D, Wilson H, et al.: Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy. Ann Rheum Dis 2002, 61:905-910.
35. Solomon DH, Kavanaugh AJ, Schur PH, et al.: Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum (Arthritis Care Res) 2002, 47:434-444.
36. Tozzoli R, Bizzaro N, Tonutti E, et al.: Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases. Am J Clin Pathol 2002, 117:316-324.
37. Tan EM, Smolen JS, McDougal JS, et al.: A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content. J Rheumatol 2002, 29:68-74.
38. Favaloro E J, Silvestrini R: Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited concensus in multilaboratory testing. Am J Clin Pathol 2002, 118:548-557.
39. Robert JM, Macara LM, Chalmers EA, et al.: Inter-assay variation in antiphospholipid antibody testing. BJOG 2002, 109;348-349.
40. Bertolaccini ML, Atsumi T, Escudero Contreras A, et al.: The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheumatol 2001, 28:2637-2643.
41. Kallarackal GU, Ansari EA, Amos N, et al.: A comparative study to assess the clinical use of Fluorescein Meniscus Time (FMT) with Tear Break Up Time (TBUT) and Schirmer's tests (ST) in the diagnosis of dry eyes. Eye 2002, 16:594-600.
42. Sanchez-Guerrero J, Aguirre-Garcia E, Perez-Dosal MR, et al.: The water test: a semi-quantitative test to screen for xerostomia. Rheumatology 2002, 41:381-389.
43. Zandbelt MM, Wentink JRM, de Wilde PCM, et al.: The synergistic value of focus score and IgA% score of sublabial salivary gland biopsy for the accuracy of the diagnosis of Sjogren's syndrome: a 10-year comparison. Rheumatology 2002, 41:819-823.
44. Sato S, Hamaguchi Y, Hasegawa M, et al.: Clinical significance of antiopoisomerase 1 antibody levels determined by ELISA in systemic sclerosis. Rheumatology 2001, 40:1135-1140.
45. Parodi A, Drosera M, Barbieri L, et al.: Scleroderma subsets are best detected by the simultaneous analysis of the autoantibody profile using commercial ELISA. Dermatology 2002, 204:29-32.
46. Scussel-Lonzetti L, Joyal F, Raynauld J-P, et al.: Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors of survival. Medicine 2002, 81:154-167.
47. Jacobsen S, Ullman S, Shen GQ, et al.: Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 2001, 28:2454-2459.
48. Russell KA, Wiegert E, Schroeder DR, et al.: Detection of antineutrophil cytoplasmic antibodies under actual clinical testing conditions. Clin Immunol 2002, 103:196-203.
49. Choi HK, Liu S, Merkel PA, et al.: Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies. J Rheumatol 2001, 28:1584-1590.
50. McLaren JS, Stimson RH, McRorie ER, et al.: The diagnostic value of antineutrophil cytoplasmic antibody testing in a routine clinical setting. OJ Med 2001, 94:615-621.
51. Mandl LA, Solomon DH, Smith EL, et al.: Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis: can test-ordering guidelines improve diagnostic accuracy? Arch Intern Med 2002, 162:1509-1514. • Selecting patients for ANCA testing based on clinical findings can reduce unnecessary tests without compromising diagnostic accuracy.
52. Salvarani C, Silingardi M, Ghirarduzzi A, et al.: Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis? Ann Intern Med 2002, 137:232-238. •• Duplex ultrasonography was not more accurate in detecting temporal arteritis than a careful physical exam.
53. Summers RM, Aggarwal NR, Sneller MC, et al.: CT virtual bronchoscopy of the central airways in patients with Wegener's granulomatosis. Chest 2002, 121:242-250.